Elisa Rumi

20.4k total citations · 3 hit papers
132 papers, 7.6k citations indexed

About

Elisa Rumi is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Elisa Rumi has authored 132 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Genetics, 84 papers in Hematology and 56 papers in Molecular Biology. Recurrent topics in Elisa Rumi's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (115 papers), Acute Myeloid Leukemia Research (59 papers) and Kruppel-like factors research (50 papers). Elisa Rumi is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (115 papers), Acute Myeloid Leukemia Research (59 papers) and Kruppel-like factors research (50 papers). Elisa Rumi collaborates with scholars based in Italy, United States and Austria. Elisa Rumi's co-authors include Mario Cazzola, Francesco Passamonti, Alessandro M. Vannucchi, Ayalew Tefferi, Daniela Pietra, Cristiana Pascutto, Mario Lazzarino, Enrica Morra, Francisco Cervantes and Heinz Gisslinger and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Elisa Rumi

125 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

2008 830 citations Francesco Passamonti, Alessandro M. Vannucchi et al. Blood profile →
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

2009 623 citations Francesco Passamonti, Alessandro M. Vannucchi et al. Blood profile →
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

2013 391 citations Elisa Rumi, Daniela Pietra et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elisa Rumi Italy	42	6.9k	5.1k	4.3k	2.8k	304	132	7.6k
Paola Guglielmelli Italy	53	8.2k 1.2×	6.2k 1.2×	5.3k 1.2×	3.3k 1.2×	330 1.1×	231	9.3k
Daniela Pietra Italy	35	3.5k 0.5×	2.9k 0.6×	2.4k 0.6×	1.4k 0.5×	201 0.7×	82	4.3k
Martin Grießhammer Germany	34	3.0k 0.4×	2.4k 0.5×	1.6k 0.4×	1.3k 0.5×	348 1.1×	153	4.1k
Christy M. Finke United States	51	6.9k 1.0×	6.3k 1.2×	4.3k 1.0×	2.5k 0.9×	317 1.0×	174	8.8k
François Delhommeau France	26	3.7k 0.5×	3.0k 0.6×	2.7k 0.6×	1.4k 0.5×	657 2.2×	81	5.2k
Terra L. Lasho United States	60	10.4k 1.5×	9.1k 1.8×	6.3k 1.5×	4.2k 1.5×	589 1.9×	254	12.8k
Nasios Fourouclas United Kingdom	7	3.1k 0.4×	2.1k 0.4×	1.9k 0.4×	1.3k 0.5×	601 2.0×	8	3.6k
S Swanton United Kingdom	8	3.1k 0.4×	2.2k 0.4×	1.9k 0.4×	1.3k 0.5×	594 2.0×	11	3.7k
Natasha Joan Curtin United Kingdom	5	3.0k 0.4×	2.0k 0.4×	1.8k 0.4×	1.3k 0.5×	578 1.9×	6	3.5k
Elisabetta Antonioli Italy	24	2.6k 0.4×	1.8k 0.4×	1.7k 0.4×	1.3k 0.5×	194 0.6×	56	3.3k

Countries citing papers authored by Elisa Rumi

Since Specialization

Citations

This map shows the geographic impact of Elisa Rumi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisa Rumi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisa Rumi more than expected).

Fields of papers citing papers by Elisa Rumi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisa Rumi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisa Rumi. The network helps show where Elisa Rumi may publish in the future.

Co-authorship network of co-authors of Elisa Rumi

This figure shows the co-authorship network connecting the top 25 collaborators of Elisa Rumi. A scholar is included among the top collaborators of Elisa Rumi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisa Rumi. Elisa Rumi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guglielmelli, Paola, Arianna Ghirardi, Alessandra Carobbio, et al.. (2025). Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real‐world ERNEST‐2 registry. HemaSphere. 9(2). e70072–e70072.

Borsani, Oscar, Daniela Pietra, Ilaria Carola Casetti, et al.. (2023). Germline MPL mutations may be a rare cause of “triple-negative” thrombocytosis. Experimental Hematology. 129. 104127–104127. 2 indexed citations

Jutzi, Jonas S., Anna E. Marneth, Ángel Guerra-Moreno, et al.. (2022). Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs. Blood. 140(11). 1291–1304. 11 indexed citations

Borsani, Oscar, Paul Bastard, Jérémie Rosain, et al.. (2022). Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms. Blood. 139(17). 2716–2720. 3 indexed citations

Borsani, Oscar, Takaki Asano, Bertrand Boisson, et al.. (2022). Isolated congenital asplenia: An overlooked cause of thrombocytosis. American Journal of Hematology. 97(8). 1110–1115. 3 indexed citations

Guglielmelli, Paola, Arianna Ghirardi, Alessandra Carobbio, et al.. (2021). Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Advances. 6(2). 373–375. 40 indexed citations

Álvarez‐Larrán, Alberto, Emanuela Sant’Antonio, Claire Harrison, et al.. (2021). Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. The Lancet Haematology. 8(9). e658–e665. 17 indexed citations

Guglielmelli, Paola, Alessandra Carobbio, Elisa Rumi, et al.. (2020). Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer Journal. 10(2). 21–21. 40 indexed citations

Carobbio, Alessandra, Paola Guglielmelli, Elisa Rumi, et al.. (2020). A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. Blood Cancer Journal. 10(10). 100–100. 15 indexed citations

10.

Rumi, Elisa, Emanuela Sant’Antonio, Chiara Cavalloni, et al.. (2020). Impaired virus‐specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib. Hematological Oncology. 38(4). 554–559. 4 indexed citations

11.

Bridgford, Jessica L., Su Min Lee, Paola Guglielmelli, et al.. (2019). Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. Blood. 135(4). 287–292. 34 indexed citations

12.

Breccia, Massimo, Claudia Baratè, Giulia Benevolo, et al.. (2019). Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice. Annals of Hematology. 99(1). 65–72. 11 indexed citations

13.

Zini, Roberta, Paola Guglielmelli, Daniela Pietra, et al.. (2017). CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. Blood Cancer Journal. 7(12). 638–638. 25 indexed citations

14.

Guglielmelli, Paola, Annalisa Pacilli, Giada Rotunno, et al.. (2017). Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 129(24). 3227–3236. 111 indexed citations

15.

Feenstra, Jelena D. Milosevic, Elisa Rumi, Daniela Pietra, et al.. (2015). Whole Exome Sequencing Reveals Clonal Evolution of Myeloproliferative Neoplasms to Acute Myeloid Leukemia. Blood. 126(23). 1626–1626. 1 indexed citations

16.

Rumi, Elisa, Daniela Pietra, Virginia Valeria Ferretti, et al.. (2013). JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 123(10). 1544–1551. 391 indexed citations breakdown →

17.

Rumi, Elisa, Ashot S. Harutyunyan, Chiara Elena, et al.. (2011). Identification of genomic aberrations associated with disease transformation by means of high‐resolution SNP array analysis in patients with myeloproliferative neoplasm. American Journal of Hematology. 86(12). 974–979. 31 indexed citations

18.

Feenstra, Jelena D. Milosevic, Tiina Berg, Thorsten Klampfl, et al.. (2011). Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. American Journal of Hematology. 87(3). 245–250. 80 indexed citations

19.

Rumi, Elisa, Ilaria Carola Casetti, Daniela Pietra, et al.. (2011). Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. American Journal of Hematology. 87(1). 129–130. 2 indexed citations

20.

Arcaini, Luca, Silvia Zibellini, Francesco Passamonti, et al.. (2009). Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. Blood Cells Molecules and Diseases. 42(3). 286–291. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact